Why is There So Much Attention on Obesity Drugs?
High U.S. prices and demand for Ozempic and Wegovy have implications for insurance premiums, public program costs, and affordability.
View the Latest: Prescription Drugs
Filter
-
-
KFF Health Tracking Poll September 2024: Support for Reducing Prescription Drug Prices Remains High, Even As Awareness of IRA Provisions Lags
FeatureMore than two years ago President Biden signed into law Medicare drug pricing provisions in the Inflation Reduction Act. KFF's September Health Tracking Poll examines voter's views on these provisions and finds that large majorities of voters are unaware of the provisions despite reporting support for them.
-
Allowing Medicare to Negotiate Drug Prices Remains Broadly Popular Among Voters, Though Most Are Unaware of the Law and Its Projected Savings
News ReleaseAllowing Medicare to negotiate drug prices on behalf of older Americans remains broadly popular across partisans, though many voters are unaware of the new law and the billions of dollars it is expected to save in 2026, a new KFF Health Tracking Poll finds.
-
What the Outcome of the Election Could Mean for Medicaid
Issue BriefThis brief examines the two presidential candidates’ records and other recent policy proposals that could inform starkly different directions for the program across key areas, including Affordable Care Act (ACA) Medicaid expansion, financing, eligibility, benefits, and cost-sharing, prescription drugs, long-term services and supports, and managed care.
-
Harris is Reframing Health as an Economic Issue
From Drew AltmanIn his latest column, KFF President and CEO Drew Altman describes how Vice President Harris has reframed health as a pocketbook economic issue, which aligns with voters’ concern about health care costs.
-
The First-Ever Government Negotiation Process for Drugs Has Finished, But the Politics Are Ongoing
PerspectiveThis post for Health Affairs Forefront examines how the results of the first-ever Medicare drug price negotiations will generate savings for the government and for Medicare beneficiaries, and how candidates' views on the issue could play a role in the upcoming elections and in the future of government negotiation.
-
While Medicare Drug Price Negotiations Don’t Apply to Private Insurance, 3.4 Million People with Employer Coverage Take at Least One of the Selected Drugs
News ReleaseAmong the 167 million people with employer-sponsored insurance in 2022, 3.4 million used at least one of the first 10 drugs identified for Medicare price negotiations.
-
How Many People with Employer-Sponsored Insurance Use the Drugs Slated for Medicare Price Negotiations
Issue BriefAmong the 167 million people with employer-sponsored insurance in 2022, 3.4 million used at least one of the first 10 drugs identified for Medicare price negotiations, according to a new analysis.
-
Compare the Candidates on Health Care Policy
FeatureThe side-by-side comparison tool provides a quick overview of former President Trump's and Vice President Harris' records, positions, public statements, and proposed policies on a range of key health care topics.
-
What Drives Health Spending in the U.S. Compared to Other Countries
Issue BriefAn updated issue brief looks at the drivers of health spending in the U.S. and key differences between the U.S. and other large, wealthy nations. The analysis finds that people in the U.S. spent $5,683 more per person on health care compared to those in similarly large and wealthy countries.